Medroxyprogesterone Acetate

Composition :

Mepogest 5 :Each Tablet contains Medroxyprogesterone Acetate BP 5 mg.

Mepogest 10 : Each Tablet contains Medroxyprogesterone Acetate BP 10 mg.

Indications:It is indicated for the treatment of-1. Dysfumction uterine bleeding 2. Mild to moderate endometriosis 3. To oppose the endometrial effects of oestrogen in menopausal women treated with oestrogen 4. Alleviation of menopausal vasomotor symptoms 5. Diagnostic uses: Primary amenorrhea, Secondary amenorhea.

Dosage and administration: Adult Dosage:Dysfunctional uterine bleeing: In dysfunctional uterine bleeding this medicine may be given in doses ranging from 5 to 10 mg for 5 to 10 days beginning on the assumed or calculated 16th to 21st day of the cycle. When bleeding is due to a deficiency of both ovarian hormones, as indicated by a poorly developed proliferative endometrium, estrogens should be used in conjunction with this medicine. If bleeding is controlled satisfactorily, two subsequent cycles of treatment should be given. Endometriosis: Beginning on the first day of the menstrual cycle, 10mg of this medicine may be given three times a day for 90 consecutive days. To oppose the Endometrial effects of estrogen in estrogen-treated post-menopausal women: 5 to 10 mg per day for at least 10 days beginning on the 16th day of a 25 day course of estrogen therapy. Progestin withdrawal bleeding should occur, beginning on the 3rd to 7th day post this medicine treatment. Menopause: 10 to 20 mg this medicine per day given continuously. Primary and secondary amenorrhea: 5 to 10mg this medicine per day for 10 days. Progestin withdrawal bleeding should ensue within 3-7 days if the endometrium has been previously primed with adequate endogenous estrogen. Pregnancy must be excluded before administration of this medicine. Or, as directed by the registered physician.

Use in Pregnancy and lactation:Medroxyprogesterone Acetate should not be used during pregnancy. There may be increased risks for hypospadias, clitoral enlargement and labial fusion in children whose mothers are exposed to Medroxyprogesterone Acetate during the first trimester of pregnancy. However, a clear association between these conditions with use of this tablet has not been established. This tablet should not be used during lactation. Detectable amounts of progestin have been identified in the breast milk of nursing mothers receiving progestins.

Packing: Mepogest 5 :Each box contains 30's tablet in a blister pack.

Mepogest 10 :Each box contains 30's tablet in a blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.